Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma | Zendy

Yaojun Zhang | Zendy; Min Shan Chen | Zendy; Yong Chen | Zendy; Wan Yee Lau | Zendy; Zhenwei Peng | Zendy

Open Access

Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma

Author(s) -

Yaojun Zhang,

Min Shan Chen,

Yong Chen,

Wan Yee Lau,

Zhenwei Peng

Publication year - 2021

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2021.26992

Subject(s) - medicine , radiofrequency ablation , hepatocellular carcinoma , transcatheter arterial chemoembolization , hazard ratio , gastroenterology , stage (stratigraphy) , randomized controlled trial , cohort , surgery , ablation , confidence interval , paleontology , biology

Key Points Question Is transcatheter arterial chemoembolization combined with radiofrequency ablation associated with better long-term survival outcomes than radiofrequency ablation alone among patients with early hepatocellular carcinoma? Findings In this cohort study of 189 patients with early hepatocellular carcinoma, patients treated with transcatheter arterial chemoembolization and radiofrequency ablation experienced better survival outcomes than those who received radiofrequency ablation alone. Meaning These results suggest that transcatheter arterial chemoembolization with radiofrequency ablation may be a better first-line treatment than radiofrequency ablation alone for patients with early hepatocellular carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research